Effective Drug Delivery to The Brain
To date, many brain conditions are poorly medicated: From neurodegeneration and stroke to brain cancers and mental disorders – limitations in drug-delivery prevent treating patients efficiently:
The prominent reason is the Blood Brain Barrier (BBB), which prevents most therapeutic molecules from reaching the brain – and severely limits the arsenal of brain therapeutics.
At NucleoTech, we develop carriers that deliver a variety of drug-classes across the BBB, including biologics and RNA drugs.
In a unique platform for shuttling therapeutics across the BBB we aim to allow a non-invasive and significantly more effective use of existing drugs.
Moreover – since Biologics and RNA drugs are generally unable to cross the BBB and induce their therapeutic effect, Our delivery platform will pave the way for using these drug classes, in a new generation of treatments – taking advantage of the many recent advances in translational research on brain conditions.
Our technology
We utilize the BBBs own transfer mechanisms to allow therapeutic molecules through, by using nanobodies (also called Single Domain Antibodies) as carrier molecules that shuttle therapeutics into the brain by the process of Receptor-Mediated Transcytosis.
Our approach has advantages in molecular size and avoiding immunogenicity. Moreover, it can be applicable to a variety of drug classes, such as biologics, RNA drugs and small molecules.
Our innovative R&D strategy allows for an In-Vivo Functional Screen to identify efficient carrier molecules that overcome the diverse mechanisms that exclude entry by the endothelial cells.
We also have exclusive access to miRNA 211, a therapeutic oligo, proprietary for treatment of epilepsy [US Patent No. 11,225,661].
Vision
At NucleoTech, we share a vision of breaking down technological barriers to promote global health.
We tread paths less taken, believing that the best advances come from being freely creative and practically
Our Team
Our team includes both scientific and operational expertise, with a track record in translational research and
business development.
founding team
Uriah Bekenstein, PhD
Naftali Cohen
Adi Koplovitz
We are blessed with a strong and close advisory of experts in the fields of Blood Brain Barrier, molecular neurobiology & Nanobody design, as well as diverse R&D expertise.
Research Team
Shachar Dagan, PHD
Head of Research
Tehila Dahan, PhD
R&D Manager
Alon Nudelman, PhD
Senior Scientist
Beata Tóth-Cohen, PhD
Research Advisor
Advisory
Prof. Hermona soreq, PhD
Molecular neurobiology expert
Prof. Alon Friedman, MD. PhD
Blood Brain Barrier expert
Maytal Foox, PhD
Pre-Clinical and Clinical R&D expertise
Maya Moran, PhD
Pre-Clinical R&D expertise
Prof. Pablo Blinder, PhD
Neurobiology and BBB microscopy expert
Prof. Niv Papo, PhD
Nanobody expert
We are looking to expand our team with competent and motivated individuals who share our vision and
passion, building a warm and collaborative working environment.
JOIN US!
